Limitations, agreements, and source contact

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma · Source last updated 2019-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

ROrlowski@mdanderson.org

organization

University of Texas (UT) MD Anderson Cancer Center

phone

713-792-2860

title

Robert Orlowski, MD, PhD / Professor, Department of Lymphoma/Myeloma

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice